AbbVie (NYSE:ABBV) Trading 2.6% Higher – Here’s What Happened

AbbVie Inc. (NYSE:ABBV)’s stock price traded up 2.6% during mid-day trading on Wednesday . The stock traded as high as $266.97 and last traded at $265.63. Approximately 5,440,532 shares changed hands during trading, a decline of 21% from the average session volume of 6,880,757 shares. The stock had previously closed at $258.92.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Acquisition financing completed: AbbVie completed a multitr tranche offering of senior notes, reported at approximately $9 billion to $10 billion, to support its planned acquisition of Apogee Therapeutics. The deal is intended to expand AbbVie’s pipeline, particularly in immunology, and may help diversify growth as Humira-related pressures continue. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition
• Neutral Sentiment: Immunology scholarship announced: AbbVie named 34 recipients of its 2026 Immunology Scholarship, marking the program’s 10th year. The announcement reinforces the company’s patient-support efforts but is unlikely to materially affect near-term earnings or valuation. AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients
• Neutral Sentiment: Positive operating backdrop: AbbVie’s latest reported quarter exceeded analyst expectations, with revenue up 10.2% year over year and quarterly guidance calling for EPS of $3.84 to $3.88. These results provide support for investor confidence, though they were not new announcements in the latest news cycle.
• Negative Sentiment: Executive stock sale: EVP and Chief Business/Strategy Officer Nicholas Donoghoe sold 32,710 AbbVie shares for approximately $8.18 million, reducing his position by about 30.5%. Insider sales can weigh modestly on sentiment, although the transaction alone does not establish a change in the company’s outlook. Nicholas Donoghoe Insider Trading Information

Wall Street Analysts Forecast Growth

ABBV has been the topic of several recent research reports. Piper Sandler reissued an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a report on Tuesday, June 23rd. BNP Paribas Exane increased their target price on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Barclays increased their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada boosted their price target on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a report on Friday, July 10th. Finally, Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average price target of $275.73.

AbbVie Price Performance

The firm’s fifty day moving average is $246.17 and its 200-day moving average is $226.63. The firm has a market cap of $469.31 billion, a price-to-earnings ratio of 75.04, a price-to-earnings-growth ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the business earned $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s payout ratio is 195.48%.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ABBV. Litman Gregory Wealth Management LLC acquired a new position in AbbVie during the 4th quarter worth approximately $28,000. Imprint Wealth LLC grew its stake in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. Burk Holdings LLC bought a new stake in shares of AbbVie during the second quarter valued at approximately $30,000. Legacy Wealth Managment LLC ID increased its holdings in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of AbbVie during the fourth quarter worth approximately $31,000. 70.23% of the stock is owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.